Brainstorm Cell Therapeutics (NasdaqCM:BCLI) in our automated value investing analysis, with the cash flow history and price comparison below.
Advertisement helps keep Trendshare free for most readers.
Estimate how long you need to hold Brainstorm Cell Therapeutics to reach your target.
Hmm, we can't give any reliable projection for Brainstorm Cell Therapeutics's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.
None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!
| Advantages | Disadvantages | Neutral |
|---|---|---|
| None. |
|
|
| BCLI Price (Brainstorm Cell Therapeutics stock price per share) |
$0.85 | |
| PE Ratio versus Sector | 100% lower than other Unknown stocks | |
| PE Ratio versus Industry | 100% lower than other Unknown stocks | |
| Free Cash Flow Jitter | 73% |
No open-market insider buys or sells are recorded for the last 12 months.
This stock has short interest! This means that people have shorted it.
Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.
As of the latest analysis, there are 566,390 shares shorted. With 13,320,540 shares available for purchase and an average trading volume over the past 10 trading days of 29,880, it would take at least 19.0 days for all of the short holders to cover their shorts.
What does this mean to you? At this volume, it'll take more than two trading weeks for shorts to cover. This may indicate a short squeeze play would work! If this stock has good fundamentals and it'll take a while for the short holders to cover, buying now could net you bigger short-term technical gains if and as the price rises.
Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth
Net income was negative in all 10 fiscal years from 2011 to 2020, so no ratio of operating cash flow to net income is shown. Operating cash flow totaled -$88.2 million over those years, against net income of -$108.9 million.
In 2020, net income was -$31.8 million and operating cash flow was -$35.2 million, so no ratio is shown for that year.
| Fiscal year | Net income (USD millions) | Operating cash flow (USD millions) | Capital expenditures (USD millions) | Operating cash flow / net income |
|---|---|---|---|---|
| 2011 | -3.9 | -2.2 | 0.0 | n/a |
| 2012 | -3.4 | -2.9 | 0.1 | n/a |
| 2013 | -4.9 | -4.1 | 0.1 | n/a |
| 2014 | -9.2 | -4.5 | 0.2 | n/a |
| 2015 | -8.5 | -7.4 | 0.0 | n/a |
| 2016 | -5.0 | -5.9 | 0.1 | n/a |
| 2017 | -5.0 | -2.4 | 0.2 | n/a |
| 2018 | -13.9 | -12.4 | 0.4 | n/a |
| 2019 | -23.3 | -11.2 | 0.5 | n/a |
| 2020 | -31.8 | -35.2 | 0.4 | n/a |
In 2020, cash and equivalents were $37.8 million against total liabilities of $15.8 million, or 239.5% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.
Total liabilities were 30.8% of total assets in 2020, compared with 45.8% in 2011, a decrease of 15.0 percentage points.
Stockholders equity was $35.5 million in 2020, compared with $1.5 million in 2011, a rise of 2283.3%.
| Fiscal year | Total assets (USD millions) | Cash and equivalents (USD millions) | Total liabilities (USD millions) | Stockholders equity (USD millions) |
|---|---|---|---|---|
| 2011 | 2.7 | 1.9 | 1.3 | 1.5 |
| 2012 | 5.1 | 1.3 | 1.2 | 4.0 |
| 2013 | 4.7 | 3.5 | 2.0 | 2.7 |
| 2014 | 9.9 | 4.3 | 3.2 | 6.7 |
| 2015 | 17.1 | 0.4 | 3.0 | 14.1 |
| 2016 | 10.8 | 0.5 | 0.9 | 9.9 |
| 2017 | 11.4 | 2.5 | 5.5 | 5.9 |
| 2018 | 11.2 | 0.9 | 6.2 | 5.0 |
| 2019 | 6.5 | 0.5 | 18.8 | -12.2 |
| 2020 | 51.3 | 37.8 | 15.8 | 35.5 |
None of the 10 fiscal years we have for Brainstorm Cell Therapeutics under its current SEC filer shows positive free cash flow.
We do not estimate a fair value for Brainstorm Cell Therapeutics while its free cash flow growth is not positive, so there is no value comparison here.
Year-to-year variability in free cash flow is volatile, measured at 73%.
No dividend yield is recorded for Brainstorm Cell Therapeutics in our data.
Before you act on any of this, read what a margin of safety means and check the company's own filings.
Every fiscal year on this page is reported by one SEC filer, CIK 1137883.
Each figure on this page comes from that filer.
Advertisement supports free stock analysis content.
Does Brainstorm Cell Therapeutics have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
This example shows how we apply the Trendshare checklist to BCLI: earnings power, cash generation, valuation, and margin of safety.
We check: business quality, free cash flow, P/E, and margin of safety.
Most Popular Articles
What is the Share Price of a Company?
What is Cash Return on Invested Capital?
When is the Right Time to Buy a Stock?
How to Make Money with Penny Stocks
Silver Price Today: XAG/USD Spot Price per Ounce, Explained